8 results
8-K
EX-99.4
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
. The comparable companies were chosen based on their similar size, or stage in the product development life cycle.
Risk-Free Interest Rate – The risk
8-K
EX-99.6
KA
Kineta Inc
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
business. Kineta works with its outside patent counsel to employ various life-cycle management patent strategies, such as managing public disclosures … and can extend the product life cycle, giving Kineta an advantage for extended patent term and a broader scope of protection for novel technologies
8-K/A
EX-99.3
dxprh83v7t gc6np
3 Feb 21
Other Events
4:59pm
- Prev
- 1
- Next